Anil Parwani, MD, PhD, explains his visions and plans for further development and integration of artificial intelligence technology in cancer diagnosis and prognosis.
Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, explains his visions and plans for further development and integration of artificial intelligence (AI) technology in cancer diagnosis and prognosis.
According to Parwani, his goal is to develop a comprehensive AI tool that functions similarly to widely-used applications like Microsoft Word or email to provide a holistic view of patient health. This tool would potentially feature advanced capabilities, including heat maps to indicate cancer location and extent. He also explains that the ideal tool would integrate various data points, including genomics and blood tests.
Transcription:
0:09 | Ultimately, what would be great is to have a tool, like a more pan AI tool, not just focused on prostate cancer or bladder cancer or gastric cancer, but this becomes an app on your monitor just like Microsoft Word or an email where, when it is launched, [we] can see a heat map of where the cancer is, how much of the cancer there is, and start to create very powerful signatures of the patient's outcomes, looking at the whole patient, not just their prostate, and getting a more integrated view of the patient with their genomics and with their blood tests.
1:01 | Ultimately, many of the many data points that we collect in medicine are in silos. They are in different systems, and the goal will be [to see] if AI can help us bring this information together to know exactly what is going on with these patients. Even though 2 patients have the same disease, their cancer is very different, even though it looks the same. So, can we go beyond just a very superficial diagnosis and grading by AI, [and] create a more comprehensive, predictive profile of their disease or their cancer and make it so it is precision pathology? My vision is to create precision pathology for every patient using these tools.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More